WINDTREE THERAPEUTICS INC /DE/ Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
WINDTREE THERAPEUTICS INC /DE/ (WINT) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.54 million as of 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-04-15
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.54M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.94M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.17M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.57M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2024-12-31 | $3.54M 10-K · filed 2025-04-15 |
| 2023-12-31 | $3.94M 10-K · filed 2025-04-15 |
| 2022-12-31 | $4.17M 10-K · filed 2024-04-16 |
| 2021-12-31 | $4.57M 10-K · filed 2023-03-31 |
| 2020-12-31 | $3.52M 10-K · filed 2022-03-31 |
| 2019-12-31 | $2.14M 10-K · filed 2021-03-29 |
| 2018-12-31 | $1.12M 10-K · filed 2020-04-03 |
| 2017-12-31 | $1.19M 10-K/A · filed 2019-04-23 |
| 2016-12-31 | $2.16M 10-K · filed 2018-04-17 |
| 2015-12-31 | $2.78M 10-K · filed 2017-03-31 |
| 2014-12-31 | $2.59M 10-K · filed 2016-03-29 |
| 2013-12-31 | $3.28M 10-K · filed 2015-03-16 |
| 2012-12-31 | $3.15M 10-K · filed 2014-03-17 |
| 2011-12-31 | $3.54M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |